Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib vs Bosutinib in CML-CP (POLARIS-2)
NCT06423911Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Feb 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of olverembatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Ascentage Pharma. Primary endpoint: Major Molecular Response Rate at 24 weeks. Started Feb 2024; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06423911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423911.